Skip to main content

Table 2 Patient characteristics

From: Decreased global myocardial perfusion at adenosine stress as a potential new biomarker for microvascular disease in systemic sclerosis: a magnetic resonance study

 

Controls

SSc patients

P

Age [years]

62 ± 11

61 ± 10

0.824

Sex [n]

female

10

17

 

male

12

2

 

BMI [kg/m2]

 

25 ± 3

26 ± 5

0.714

LVM/BSA [g/m2]

 

58 ± 11

54 ± 12

0.089

EDV/BSA [ml/m2]

 

84 ± 12

76 ± 12

0.036*

ESV/BSA [ml]

 

32 ± 8

27 ± 7

0.069

CI [l/min/m2]

 

3.2 ± 0.4

3.6 ± 0.6

0.014

Skin involvement [n]

diffuse

 

7

 

limited

 

12

 

Disease duration [years]

  

10 ± 6

 

Antibody [n]

ANA

 

6

 

ACA

 

5

 

ARA

 

5

 

ATA

 

6

 

PAH [n]

  

1

 

VC % expected

  

96 ± 12

 

DLCO % expected

  

80 ± 19

 

VC % predicted / DLCO % predicted

  

1.3 ± 0.3

 

Uric acid [μmol/L]

  

262 ± 59

 

Telangiectasias [n]

  

14

 

Pitting scars [n]

  

5

 

Nailfold capillary density [loops/mm]

  

5.0 ± 1.3

 

Skin score < 10 [n]

  

18

 

Skin score 10–20 [n]

  

1

 

Skin score > 20 [n]

  

1

 

Nifedipine [n]

  

12

 

ERA [n]

  

2

 

PDE5I [n]

  

5

 
  1. Continues variables are presented as mean ± SD. * P < 0.05
  2. BSA body surface area, BMI Body mass index, LVM left ventricular mass, LV EDV left ventricular end diastolic volume, LV ESV left ventricular end systolic volume, CI cardiac index, PAH pulmonary arterial hypertension, VC vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, ANA anti nuclear antibodies other than ACA, ARA or ATA, ACA anti centromeric antibodies, ARA anti RNA polymerase III antibodies, ATA anti topoisomerase I antibodies, ERA endothelin receptor antagonist, PDE5I phosphodiesterase type 5 inhibitor